The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

NCT05005741 on ClinicalTrials.gov · last registry update 2023-03-17

120 participants. Its estimated completion date, 31 December 2023, has passed with no update to the record. Primary outcome, as filed: haemoglobin A1c(HbA1c). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. dulaglutide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: Second Xiangya Hospital of Central South University
Sponsor type: Other
Enrollment: 120
Started: 2021-05-01
Primary completion: 2023-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

haemoglobin A1c(HbA1c)

Conditions studied

Diabetes Mellitus, Type 2 · Overweight or Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.